CAS 19171-19-8 Pharmaceutical Pomalidomide Antitumor Pharmaceutical
Prouct Description
Product Details
| Product Name |
Pomalidomide |
| Apperance |
yellow powder |
| CAS |
19171-19-8 |
| MF |
C13H11N3O4 |
| MW |
273.24 |
Bomalidomide is a third-generation immunomodulatory drug (IMiD). Its chemical structure is similar to that of Thalidomide and Lenalidomide, but it has stronger immunomodulatory and anti-tumor activities. It exerts therapeutic effects through multiple mechanisms and is mainly used in the treatment of multiple myeloma (MM), especially showing significant efficacy for other patients resistant to IMiDs. Pomalidomide was first approved by the FDA in 2013 and is now included in clinical guidelines for many countries around the world.
Application&Function
Anti-tumor effect
Direct inhibition of myeloma cells: By interfering with the tumor microenvironment, it inhibits the proliferation of cancer cells and induces apoptosis.
Inhibit angiogenesis: Block angiogenic factors such as to reduce blood supply to tumors.
Immune regulatory function
Enhance the activity of T cells and NK cells: Promote the secretion of cytokines such as IL-2 and IFN-γ, and improve immune surveillance capabilities.
Regulate immune checkpoints: Down-regulate inhibitory signaling pathways such as PD-1/PD-L1.
Epigenetic regulation
By binding to the CRBN (Cereblon) protein, it targets and degrades the Ikaros (IKZF1) and Aiolos (IKZF3) transcription factors, thereby affecting the survival of tumor cells.
Anti-inflammatory effect
It inhibits pro-inflammatory factors such as TNF-α and IL-6 and is used to treat inflammation-related diseases such as myelofibrosis.
Advantages of combined treatment
When used in combination or proteasome inhibitors (such as bortezomib), it can significantly enhance the therapeutic effect and prolong progression-free survival (PFS).
Low cross-resistance
It may still be effective for patients resistant to thalidomide/lenalidomide and is an important option for refractory multiple myeloma (MM).
Specification
ABOUT US
){kind=link}